Cited by 120Advanced Drug Delivery SystemsRetinal Diseases and TreatmentsOcular Infections and Treatments

Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside

Open access
Rowe-Rendleman, Cheryl L., Durazo, Shelley A., Kompella, Uday B., Rittenhouse, Kay D., Di Polo, Adriana, Weiner, Alan L., Grossniklaus, Hans E., Naash, Muna I. +3 more·2014·Investigative Opthalmology & Visual Science

Abstract

the University of Colorado Anschutz Medical Campus in Aurora, Colorado.The SERC provided a diverse group of approximately 150 scientists and physicians representing industry and academia from 14 countries with a unique opportunity to explore the latest approaches to drug and gene delivery to the posterior segment of the eye.Unlike the 2009 SERC meeting, which focused on novel drug delivery platforms while elucidating the anatomic barriers to reach the posterior segment, 1 the most recent meeting explored strategies for bypassing ocular barriers using novel materials, nanoparticulate delivery systems, and gene therapy.It brought together experts in both ophthalmology and tangentially related areas to discuss the application and inherent technical challenges for translating experimental results from the laboratory bench to dependable medical therapies at the bedside and, where possible, it exemplified findings in ocular models with methods and results gleaned from disciplines outside of ophthalmology.The present review of the SERC provides investigators with tools to navigate these nascent approaches by exploring strategies from key laboratory investigations, drug development specialists, and clinical trials.The 2-day conference comprised the following six sessions: (1) barriers to drug delivery and transporter-guided drug design; (2) drug/gene delivery systems and cell therapies for the eye; (3) pharmacokinetics (PK), pharmacodynamics, and alternative routes of drug delivery; (4) nanotechnology for diagnosis and treatment of posterior eye disease; (5) translation of gene delivery for posterior eye disease; and (6) clinical trials.Rather than being a deliberate summary of each presentation, this review describes the common themes expressed during the six sessions.

Integrity signals

Registry

Crossref · 10.1167/iovs.13-13707

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., & Edelhauser, H. F.
Affiliations
  • Omar Consulting Group, LLC, Princeton Junction, New Jersey, United States
  • University of Colorado Anschutz (US)
  • Pfizer (United States) (US)
  • University of Montreal, Montreal, Quebec, Canada
  • DrugDel Consulting, LLC, Arlington, Texas, United States
  • Emory University (US)
  • University of Oklahoma Health Sciences Center (US)
  • University of Florida (US)
  • University of Southern California (US)
Corresponding author
Kompella, Uday B.
Venue
Investigative Opthalmology & Visual Science
Published
2014-04-28
Volume
55
Issue
4
Pages
2714
ISSN
  • 0146-0404 (ISSN-L)
  • 1552-5783
OpenAlex
W2027841369
Cited by
120
References
71
Citations by year
2026: 2 · 2025: 13 · 2024: 4 · 2023: 11 · 2022: 7 · 2021: 12 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 13 · 2016: 17 · 2015: 6 · 2014: 1
FWCI
6.98
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Investigative Ophthalmology & Visual Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (1r13ey021956-01)
  • National Eye Institute (R13 EY021956, R01EY018656, 1R13EY021956-01, R01EY022778, P30EY006360)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
posterior segment drug delivery, gene therapy delivery, nanoparticle drug delivery, pharmacokinetics, pharmacodynamics, clinical trials, translational research
MeSH terms
Pharmaceutical Preparations, Humans, Retinal Diseases, Genetic Therapy, Drug Delivery Systems, Gene Transfer Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review